Pharmacology of Exenatide in Pediatric Sepsis, PEPS is a phase 1-2 research study that will
examine drug safety, drug metabolism, drug action and preliminary drug clinical effects of
four does of exenatide injected every 12 hours to children with shock from infection (septic
shock). The investigators hypothesize that exenatide can be safely dosed to children with
sepsis to achieve blood levels of drug similar to that achieved in teenagers with type 2
diabetes. The investigators further hypothesize that injection of exenatide to children with
septic shock will normalize blood glucose levels and decrease levels of inflammation proteins
in the blood during the early course of sepsis.